Myths vs facts: ApoB and Wechseljahre

Myth: 'ApoB is only relevant for men.' Fact: After menopause, women's cardiovascular risk rises sharply, and ApoB is a key marker. Estrogen enhances LDL receptor activity and clearance of ApoB-containing lipoproteins. With estrogen decline, LDL-C and especially ApoB increase, often surpassing levels in age-matched men. Myth: 'ApoB is just another way to measure LDL-C.' Fact: ApoB counts all atherogenic particles (LDL, VLDL, IDL, Lp(a)), while LDL-C only measures cholesterol mass. In menopausal women with small, dense LDL, LDL-C may appear normal despite elevated ApoB. Myth: 'ApoB testing is unnecessary if standard lipids are normal.' Fact: ApoB is an independent risk factor and can be elevated even when LDL-C is normal. Guidelines increasingly recommend ApoB as a treatment target for cardiovascular prevention, especially in postmenopausal women. Caveat: A single measurement is not diagnostic; lifestyle, diet, and family history matter. Evidence is strong (prospective studies, meta-analyses), but not everyone benefits equally from ApoB reduction.